BioLineRx (NASDAQ:BLRX) Rating Increased to Sell at StockNews.com

StockNews.com upgraded shares of BioLineRx (NASDAQ:BLRX) to a sell rating in a research report sent to investors on Tuesday.

Separately, HC Wainwright reiterated a buy rating and issued a $21.00 target price on shares of BioLineRx in a research note on Wednesday, April 17th.

BioLineRx Price Performance

Shares of BLRX opened at $0.64 on Tuesday. The business’s 50-day moving average is $1.04 and its two-hundred day moving average is $1.32. The company has a market capitalization of $50.91 million, a P/E ratio of -0.71 and a beta of 1.38. BioLineRx has a fifty-two week low of $0.61 and a fifty-two week high of $2.53. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.47 and a current ratio of 1.53.

BioLineRx (NASDAQ:BLRX) last posted its earnings results on Thursday, March 28th. The biotechnology company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.07. The company had revenue of $4.80 million for the quarter, compared to analyst estimates of $0.17 million. During the same period last year, the business earned ($0.09) earnings per share. Research analysts predict that BioLineRx will post -1.03 earnings per share for the current year.

Hedge Funds Weigh In On BioLineRx

Several institutional investors and hedge funds have recently modified their holdings of BLRX. Values First Advisors Inc. purchased a new position in BioLineRx during the third quarter worth approximately $88,000. Rathbones Group PLC acquired a new position in shares of BioLineRx during the 3rd quarter worth approximately $72,000. Allen Mooney & Barnes Investment Advisors LLC purchased a new position in shares of BioLineRx during the 3rd quarter valued at approximately $46,000. B. Riley Wealth Advisors Inc. grew its stake in BioLineRx by 88.5% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 21,300 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 10,000 shares during the period. Finally, NorthRock Partners LLC acquired a new stake in BioLineRx in the 4th quarter valued at $27,000. Hedge funds and other institutional investors own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.